AssessmentsNeurocutaneous disorders: Pathology review
USMLE® Step 1 style questions USMLE
A 29-year-old man comes to the clinic due to headaches and feeling unstable. Over the past 6 months, the patient gradually has been falling more frequently. He has also been experiencing constant headaches which are worse in the morning. He denies any trauma and does not use alcohol illicit drugs. Medical history is notable for pheochromocytoma, treated with surgery 6 months ago. Vitals are within normal limits. On physical examination, he has difficulty ambulating or standing with feet close together. An MRI is obtained and shown below:
Reproduced from: Wikimedia Commons
Histopathological analysis of this patient's lesion would most likely show which of the following?
Content Reviewers:Yifan Xiao, MD
At the family medicine clinic, a 17 year old male named Heath came in because of lower back pain. Clinical examination reveals lots of small growths on the face, light flat patches throughout his body, and a darker raised patch on his forehead. Heath was adopted early in his life and his family history is unknown. Abdominal ultrasound reveals an angiomyolipoma of the left kidney. Next to Heath, there’s an 8 year old child named Sylvia. Sylvia complains of difficulty seeing what the teacher is writing in school. She also has a purple mark that covers the forehead and her right upper eyelid. Eye examination reveals increased intraocular pressure in the right eye. Her medical history includes an episode of seizure when she was 5 years old. A brain MRI is ordered and reveals brain atrophy. Finally, there’s a 45 year old male named Austin who came in because of a ringing sound in his ears and a gradual loss of hearing. Brain MRI reveals bilateral masses on the cerebellopontine angle.
Okay, so all of them have a neurocutaneous syndrome. Neurocutaneous syndromes primarily affect the nervous system and the skin. They include Sturge-Weber syndrome, tuberous sclerosis, neurofibromatosis type I and II, and Von Hippel-Lindau disease. For the exams remember that Sturge-Weber occurs due to sporadic mutations, while tuberous sclerosis, neurofibromatosis type I and II, and Von Hippel-Lindau disease are autosomal dominant conditions.
Alright, now let’s take a closer look at these different disorders, starting with Sturge-Weber syndrome, which is also known as encephalotrigeminal angiomatosis. During week 6 of development, as the cephalic portion of the neural tube grows, a network of tiny blood vessels called a vascular plexus develops. There’s a gene called the GNAQ gene which codes for a guanine nucleotide-binding protein that is involved in the development of that plexus. Normally, around week 9, the GNAQ gene stops getting expressed, leading to the regression of the vascular plexus. But in Sturge-Weber syndrome, a sporadic mutation occurs that let some cells keep making GNAQ proteins. The mutated cell then replicates over and over, so all of the cells that descend from it have the mutation.
The earlier the mutation arises in embryological development, the more tissues will be affected, since more tissues will originate from the mutant cells. This is an example of somatic mosaicism. This means the individuals have some cells in their body with the mutation and others with the normal gene. Now as the GNAQ proteins accumulate, it results in the excessive growth of capillaries in tissues that derive from the ectoderm, especially the brain, eyes, and facial skin. The most common presentation is unilateral and complete disease, meaning it affects both the brain and the face on the same side, and most often the eye is not involved.
Okay, moving onto tuberous sclerosis. This disorder occurs when there’s a mutation in either the TSC1 gene on chromosome 9, or TSC2 on chromosome 16. TSC1 encodes for the protein hamartin and TSC2 for the protein tuberin. These two proteins combine to form hamartin-tuberin complex, which binds to and inhibits another protein called mechanistic target of rapamycin, or mTOR. Normally, mTOR increases cell proliferation and so the hamartin-tuberin protein complex acts as a tumor suppressor.
So when there’s a mutation in the TSC genes, it causes an altered hamartin-tuberin protein complex that’s unable to switch off mTOR. As a result, benign tumors and growths made of a variety of cell types, called hamartomas, form throughout the body. Also, the lifetime risk of cancer is increased. The brain and the skin are usually affected the most, along with the kidneys, heart, lungs, and eyes.
Now, let’s move onto neurofibromatoses. There are two types, type I and type II, and they’re caused by mutations in the NF1 or NF2 gene, which are found on chromosomes 17 and 22, respectively. For the test, remember, NF1 goes with chromosome 17 and NF2 goes with chromosome 22. Normally, these are tumor suppressor genes that code for neurofibromin and merlin proteins. Merlin is a protein found in the cytoskeleton of neurons and its tumor inhibitory mechanism isn’t fully understood. You’re much more likely to be asked about the mechanism of type I neurofibromtaosis and neurofibromin, which inactivates the RAS pathway. The RAS pathway takes part in many other signaling pathways responsible for cell growth, so dysregulation leads to the growth of neurofibromas which are benign, fibrous tumors that originate from neurons. For neurofibromatosis type II, a high yield fact is that it mainly causes schwannomas which arise from schwann cells.
Finally, Von-Hippel-Lindau disease is caused by a mutation of the von-Hippel-Lindau or VHL gene that is located on the short arm of chromosome 3. The VHL gene is a tumor suppressor gene that codes for proteins in charge of degrading a transcription factor called hypoxia-inducible-factor, or HIF. HIF is responsible for up-regulating genes that code for platelet-derived and vascular endothelial growth factors, or PDGF and VEGF, both of which promote new blood vessel formation and cell growth. In VHL disease, this tumor suppressor gene is mutated or deleted, causing an increase in hypoxia-inducible-growth factor, which increases the levels of PDGF and VEGF and ultimately the risk of tumor formation. So, VHL disease is characterized by the development of benign and malignant tumors in various organs, such as the eyes, kidneys, adrenal glands, CNS, and pancreas.
Alright, now all neurocutaneous syndromes typically present with skin lesions, neurological signs, and formation of various tumors. But each of the neurocutaneous syndromes have symptoms that are special to them and can help you identify them. Let’s start with Sturge-Weber syndrome. The first high yield symptoms is the characteristic nevus flammeus, which is a non-neoplastic birthmark. This is also known as a port wine stain, and it’s a purple mark on the face in the areas innervated by the trigeminal nerve. The trigeminal nerve, especially the ophthalmic and maxillary distributions, are involved because during embryological development, it’s one of the first cranial nerves to develop from neural crest cells. Typically, the port wine stain covers the forehead and upper eyelid on one side of the face, but in some individuals, it covers the whole face.
Now, in the brain, some individuals develop leptomeningeal angiomas, which are vascular malformations in the meninges that lead to pooling of blood, impaired venous drainage, and brain ischemia. Ischemia causes brain atrophy which relates to the extent of neurolo